Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0008 |
mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |
mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.099 | 0.003 |
mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.003 |
mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |
mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.083 | 0.004 |
mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.097 | 0.004 |
mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.092 | 0.005 |
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.079 | 0.005 |